文献速递中医内科中药与中成药合理使用

中医宗气理论与肠道菌群调控:肝细胞癌治疗的战略靶点

The Central Qi theory in traditional Chinese medicine: Gut microbiota modulation as a strategic target for hepatocellular carcinoma therapy.
PubMed 文献 · J Ethnopharmacol · 2026-01-08

ETHNOPHARMACOLOGICAL RELEVANCE: Patients with intermediate and advanced hepatocellular carcinoma (HCC) often derive limited benefit from systemic therapy and experience a substantial symptom burden with deterioration in quality of life.…

要点

  • 宗气亏虚可连接消化受损、能量代谢紊乱、菌群失调与免疫低下。
  • 补中益气类中药可富集有益菌、减少致病菌并改善菌群代谢物谱。
  • 现有证据多为关联性且来自非肝癌模型,临床意义尚不确定。

核心结论

  • 宗气亏虚为肝细胞癌中消化受损、能量代谢紊乱、菌群失调与免疫应答降低提供生物学上合理的概念框架。
  • 补中益气类中药调节肠道菌群可能带来代谢与免疫支持获益,但当前证据初步、以关联性为主,需谨慎解读。

主要发现

  • 菌群失调破坏胆汁酸、短链脂肪酸与色氨酸代谢途径并损害肠道屏障,加重食欲调节与能量失衡并削弱抗肿瘤免疫。
  • 补中益气类中药被报道可富集有益菌群、减少病原菌与致病共生菌、改善微生物代谢物谱并恢复屏障完整性。
  • 上述发现异质性大且主要来自非肝细胞癌模型,早期探索性数据提示可能与免疫检查点抑制剂存在相互作用,但临床意义不确定。

临床怎么用

  • 可将补中益气类中药作为辅助或替代选项,用于缓解症状、改善生活质量及提高标准治疗耐受性与依从性。
  • 临床应用需认识现有证据的初步性与异质性,避免夸大对肝细胞癌的直接疗效。

局限性

  • 因果关系、肝细胞癌特异性机制与临床效应一致性等关键不确定性仍存。
  • 现有证据主要基于关联性发现且多来自非肝细胞癌模型。
  • 未来需标准化制剂、机制验证、生物标志物指导分层及严谨设计的临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Patients with intermediate and advanced hepatocellular carcinoma (HCC) often derive limited benefit from systemic therapy and experience a substantial symptom burden with deterioration in quality of life. These challenges underscore the need for safe, effective adjunctive or alternative therapies. The traditional Chinese medicine concept of Central Qi shows conceptual contemporary with contemporary understanding of the gut-liver axis and microbiome biology. Chinese herbal medicines centered on tonifying the central and replenishing qi (Buzhong Yiqi) are considered adjunctive or alternative therapeutic options for alleviating symptoms, improving quality of life, and enhancing tolerance and adherence to standard treatments. AIM OF THIS REVIEW: To delineate links among the interrelations among Central Qi, the gut microbiota, and HCC, to synthesize evidence on how Buzhong Yiqi medicines modulate the gut microbiota, and to elucidate the proposed mechanistic bases for their potential adjunctive effects in HCC. This review aims to provide a biologically plausible framework to inform microbiome-based mechanistic research and clinical translation. METHODS: Databases including PubMed, Web of Science, Elsevier ScienceDirect, CNKI, and Google Scholar were searched using predefined terms related to hepatocellular carcinoma, gut microbiota, and the gut-liver axis, nutrient absorption, metabolic regulation, immune modulation, and Buzhong Yiqi medicines, as well as their representative herbs. In vivo, in vitro, and clinical studies published from 2000 to October 2025 were included. RESULTS: Dysbiosis disrupts the metabolic pathways of bile acid, short-chain fatty acid, and tryptophan metabolic pathways, while compromising the intestinal barrier. This disruption can worsen appetite regulation and energy imbalance, as well as weaken antitumor immunity. Buzhong Yiqi medicines have been reported to enrich beneficial taxa, reduce pathogens and pathobionts, and improve microbial metabolite profiles, restoration of barrier integrity, improvements in nutrient intake and energy homeostasis. These findings are heterogeneous and largely derived from non-HCC models, but collectively suggest potential support of metabolic and immune homeostasis, with possible influence on the tumor immune microenvironment. Early exploratory data also indicate a potential interaction with immune checkpoint inhibitors, although its clinical significance remains uncertain. CONCLUSION: Central Qi deficiency provides a biologically plausible conceptual framework linking impaired digestion, disrupted energy metabolism, microbial dysbiosis, and reduced immune responsiveness in HCC. Modulation of the GM through Buzhong Yiqi medicines may offer supportive metabolic and immunological benefits, but current evidence is preliminary, based mainly on associative findings, and requires cautious interpretation. Key uncertainties remain regarding causal relationships, HCC-specific mechanisms, and the consistency of clinical effects. Future research should prioritize standardized preparations, mechanistic validation, biomarker-guided stratification, and rigorously designed clinical trials to clarify the clinical relevance of these proposed pathways and to advance global acceptance of integrative therapy.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Tao H, Mao K, et al. The Central Qi theory in traditional Chinese medicine: Gut microbiota modulation as a strategic target for hepatocellular carcinoma therapy. J Ethnopharmacol. 2026. PMID: 41519187. doi:10.1016/j.jep.2025.121147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。